In vivo molecular imaging of PD-L1 using antibodies labeled with radioisotopes or fluorescent probes has shown distinct advantages over IHC in pre-clinical tumor models (5, 24–26), encouraging further development of molecular imaging for noninvasive assessment of PD-L1 expression. This evidence concerns the gene CD274 and neoplasm.